Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 10:40pm CEST

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
06/23 AMGEN : Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) Fo..
06/22 INVESTIGATORS AT AMGEN REPORT FINDIN : Regulatory...
06/22 AMGEN : Findings on Chromatography Detailed by Investigators at Amgen (Evidence ..
06/22 AMGEN : AAM Biosimilars Council Praises Unanimous Supreme Court Ruling That Will..
06/22 AMGEN : Researchers Submit Patent Application, "Process Control Systems and Meth..
06/22 AMGEN : Today's Research Reports on Stocks to Watch: Amgen and Incyte
06/21 AMGEN : To Present New Data At 22nd Congress of the European Hematology Associat..
06/19 AMGEN : FDA Accepts Amgen's Supplemental Biologics License Application To Expand..
06/15 AMGEN : New Diverticulitis Study Findings Have Been Reported from Amgen (Sequenc..
06/15 AMGEN : And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, ..
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06/26 BIOTECH BOOM! : Overview And Company-By-Company Review
06/26 Recent Stock Purchase June 2017
06/23 European Ad Com backs pediatric formulation of Amgen's Mimpara
06/23 Premarket analyst action - healthcare
06/22 FDA rejects Pfizer's marketing application for Epogen biosimilar
Advertisement
Financials ($)
Sales 2017 22 637 M
EBIT 2017 11 757 M
Net income 2017 8 151 M
Debt 2017 2 923 M
Yield 2017 2,60%
P/E ratio 2017 15,71
P/E ratio 2018 15,49
EV / Sales 2017 5,77x
EV / Sales 2018 5,29x
Capitalization 127 717 M
More Financials
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 181 $
Spread / Average Target 4,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN18.78%126 856
CELGENE CORPORATION15.64%104 873
GILEAD SCIENCES-0.52%92 150
REGENERON PHARMACEUTIC..40.93%54 987
VERTEX PHARMACEUTICALS81.09%33 251
ACTELION23.36%30 469
More Results